Global Short Bowel Syndrome (SBS) Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Short Bowel Syndrome (SBS) Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Short bowel syndrome (SBS) is a metabolic disorder occurs when the portion of the small intestine is not functioning or removed through surgery due to digestive illness. SBS is caused by lack of function of the small intestine. This results in malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition.
The global Short Bowel Syndrome (SBS) Drugs market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
During 2017, the parental route segment accounted for the major shares and dominated the SBS market. Factors such as the rapid action mechanism of the drug and the prolonged action result contribute to the growth of this market segment in the coming years. In the parental route, the drug is administered intravenously, subcutaneously, intrathecally, or through intramuscular routes and is applied when the oral route of drug administration is ineffective.
In terms of sales (consumption) side, this report focuses on the sales of Short Bowel Syndrome (SBS) Drugs by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Short Bowel Syndrome (SBS) Drugs market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Short Bowel Syndrome (SBS) Drugs market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.
Merck
Takeda
Emmaus Medical
Ardelyx
Naia Pharmaceuticals
Nutrinia
OxThera
Sancilio Pharmaceuticals
Zealand Pharma
By Type
Glucagon-Like Peptide-2 (GLP-2)
Growth Hormone
Glutamine
Other
By Sale Channel
Hospitals
Clinics
Retail Pharmacies
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by sale channel, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Short Bowel Syndrome (SBS) Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Short Bowel Syndrome (SBS) Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by sale channel, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by sale channel and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by sale channel and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by sale channel, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by sale channel and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by sale channel and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Short Bowel Syndrome (SBS) Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.
The global Short Bowel Syndrome (SBS) Drugs market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
During 2017, the parental route segment accounted for the major shares and dominated the SBS market. Factors such as the rapid action mechanism of the drug and the prolonged action result contribute to the growth of this market segment in the coming years. In the parental route, the drug is administered intravenously, subcutaneously, intrathecally, or through intramuscular routes and is applied when the oral route of drug administration is ineffective.
In terms of sales (consumption) side, this report focuses on the sales of Short Bowel Syndrome (SBS) Drugs by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Short Bowel Syndrome (SBS) Drugs market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Short Bowel Syndrome (SBS) Drugs market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.
By Company
Merck
Takeda
Emmaus Medical
Ardelyx
Naia Pharmaceuticals
Nutrinia
OxThera
Sancilio Pharmaceuticals
Zealand Pharma
By Type
Glucagon-Like Peptide-2 (GLP-2)
Growth Hormone
Glutamine
Other
By Sale Channel
Hospitals
Clinics
Retail Pharmacies
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by sale channel, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Short Bowel Syndrome (SBS) Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Short Bowel Syndrome (SBS) Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by sale channel, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by sale channel and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by sale channel and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by sale channel, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by sale channel and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by sale channel and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Short Bowel Syndrome (SBS) Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices